These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 23338154)

  • 1. The discordance between primary breast cancer lesions and pulmonary metastatic lesions in expression of aldehyde dehydrogenase 1-positive cancer cells.
    Nogami T; Shien T; Tanaka T; Doihara H; Taira N; Takabatake D; Nishimura R; Nishiyama K; Mizoo T; Ohsumi S
    Breast Cancer; 2014 Nov; 21(6):698-702. PubMed ID: 23338154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of ALDH1 in axillary lymph node metastases is a prognostic factor of poor clinical outcome in breast cancer patients with 1-3 lymph node metastases.
    Nogami T; Shien T; Tanaka T; Nishiyama K; Mizoo T; Iwamto T; Ikeda H; Taira N; Doihara H; Miyoshi S
    Breast Cancer; 2014 Jan; 21(1):58-65. PubMed ID: 22407396
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aldehyde dehydrogenase 1-positive cells in axillary lymph node metastases after chemotherapy as a prognostic factor in patients with lymph node-positive breast cancer.
    Sakakibara M; Fujimori T; Miyoshi T; Nagashima T; Fujimoto H; Suzuki HT; Ohki Y; Fushimi K; Yokomizo J; Nakatani Y; Miyazaki M
    Cancer; 2012 Aug; 118(16):3899-910. PubMed ID: 22180194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunohistochemical detection of breast cancer stem cells in hormone receptor-positive breast cancer and their role in response to endocrine therapy and clinical outcome.
    Hashimoto K; Shimizu C; Tsuda H; Saji S; Osaki A; Shigekawa T; Aogi K
    Oncology; 2012; 82(3):168-74. PubMed ID: 22433454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in expression of the cancer stem cell marker aldehyde dehydrogenase 1 among estrogen receptor-positive/human epidermal growth factor receptor type 2-negative breast cancer cases with early, late, and no recurrence.
    Miyoshi Y; Shien T; Ogiya A; Ishida N; Yamazaki K; Horii R; Horimoto Y; Masuda N; Yasojima H; Inao T; Osako T; Takahashi M; Tomioka N; Endo Y; Hosoda M; Doihara H; Miyoshi S; Yamashita H;
    Breast Cancer Res; 2016 Jul; 18(1):73. PubMed ID: 27368476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Receptor expression discrepancy between primary and metastatic breast cancer lesions.
    Karagöz Özen DS; Ozturk MA; Aydin Ö; Turna ZH; Ilvan S; Özgüroglu M
    Oncol Res Treat; 2014; 37(11):622-6. PubMed ID: 25427579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Discordance of estrogen receptor (ER), progestin receptor (PR), and HER-2 receptor statuses between primary and metastatic focuses of breast cancer].
    Wang B; Guan ZZ; Liu DG; Lin TY; Zhang L; Xia ZJ; Teng XY
    Ai Zheng; 2004 Dec; 23(12):1710-3. PubMed ID: 15601567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discordant expression of hormone receptors and HER2 in breast cancer. A retrospective comparison of primary tumors with paired metachronous recurrences or metastases.
    Arapantoni-Dadioti P; Valavanis C; Gavressea T; Tzaida O; Trihia H; Lekka I
    J BUON; 2012; 17(2):277-83. PubMed ID: 22740206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological analysis of breast ductal carcinoma in situ with ALDH1-positive cancer stem cells.
    Tsukabe M; Shimazu K; Morimoto K; Naoi Y; Kagara N; Shimoda M; Shimomura A; Maruyama N; Kim SJ; Noguchi S
    Oncology; 2013; 85(4):248-56. PubMed ID: 24192633
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis.
    St Romain P; Madan R; Tawfik OW; Damjanov I; Fan F
    Hum Pathol; 2012 Mar; 43(3):398-404. PubMed ID: 21840040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
    Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
    Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stem cell marker aldehyde dehydrogenase 1-positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression.
    Morimoto K; Kim SJ; Tanei T; Shimazu K; Tanji Y; Taguchi T; Tamaki Y; Terada N; Noguchi S
    Cancer Sci; 2009 Jun; 100(6):1062-8. PubMed ID: 19385968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical outcome of receptor expression discordance between primary and metastatic breast cancer].
    Mu YX; Zhang P; Ma F; Yuan P; Wang JY; Xu BH; Li Q
    Zhonghua Zhong Liu Za Zhi; 2018 Jul; 40(7):506-511. PubMed ID: 30060358
    [No Abstract]   [Full Text] [Related]  

  • 14. Evaluation of aldehyde dehydrogenase 1 and transcription factors in both primary breast cancer and axillary lymph node metastases as a prognostic factor.
    Ito M; Shien T; Omori M; Mizoo T; Iwamoto T; Nogami T; Motoki T; Taira N; Doihara H; Miyoshi S
    Breast Cancer; 2016 May; 23(3):437-44. PubMed ID: 25599843
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact.
    Ibrahim T; Farolfi A; Scarpi E; Mercatali L; Medri L; Ricci M; Nanni O; Serra L; Amadori D
    Oncology; 2013; 84(3):150-7. PubMed ID: 23257904
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Luminal subtypes predict improved survival following central nervous system metastasis in patients with surgically managed metastatic breast carcinoma.
    Wiens AL; Martin SE; Bertsch EC; Vance GH; Stohler RA; Cheng L; Badve S; Hattab EM
    Arch Pathol Lab Med; 2014 Feb; 138(2):175-81. PubMed ID: 24476516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discordant hormone receptor and human epidermal growth factor receptor 2 status in bone metastases compared to primary breast cancer.
    Aurilio G; Monfardini L; Rizzo S; Sciandivasci A; Preda L; Bagnardi V; Disalvatore D; Pruneri G; Munzone E; Della Vigna P; Renne G; Bellomi M; Curigliano G; Goldhirsch A; Nolè F
    Acta Oncol; 2013 Nov; 52(8):1649-56. PubMed ID: 23327413
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node-positive breast cancers: a long-term follow-up study.
    Yoshioka T; Umekita Y; Ohi Y; Souda M; Sagara Y; Sagara Y; Sagara Y; Rai Y; Tanimoto A
    Histopathology; 2011 Mar; 58(4):608-16. PubMed ID: 21371077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expressions of ER, PR, HER-2, COX-2, and VEGF in primary and relapsed/metastatic breast cancers.
    Sun L; Yu DH; Sun SY; Zhuo SC; Cao SS; Wei L
    Cell Biochem Biophys; 2014 Apr; 68(3):511-6. PubMed ID: 23955549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessment of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status in the fine needle aspirates of metastatic breast carcinomas.
    Monaco SE; Wu Y; Teot LA; Cai G
    Diagn Cytopathol; 2013 Apr; 41(4):308-15. PubMed ID: 22045649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.